Rep. Josh Gottheimer Buys AbbVie Inc. (NYSE:ABBV) Stock

Representative Josh Gottheimer (D-New Jersey) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on May 14th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on April 1st. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of RTX NYSE: RTX on 4/23/2025.
• Purchased $1,001 - $15,000 in shares of Cheniere Energy NYSE: LNG on 4/22/2025.
• Purchased $1,001 - $15,000 in shares of Techtronic Industries OTCMKTS: TTNDY on 4/21/2025.
• Purchased $1,001 - $15,000 in shares of Tri Pointe Homes NYSE: TPH on 4/21/2025.
• Purchased $1,001 - $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk NYSE: TLK on 4/21/2025.
• Sold $1,001 - $15,000 in shares of KKR & Co. Inc. NYSE: KKR on 4/21/2025.
• Purchased $1,001 - $15,000 in shares of D.R. Horton NYSE: DHI on 4/21/2025.
• Purchased $1,001 - $15,000 in shares of Home Depot NYSE: HD on 4/21/2025.
• Sold $1,001 - $15,000 in shares of Hillman Solutions NASDAQ: HLMN on 4/17/2025.
• Sold $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 4/17/2025.

AbbVie Price Performance

NYSE:ABBV traded up $1.20 during trading hours on Friday, hitting $182.88. 3,320,918 shares of the stock were exchanged, compared to its average volume of 7,375,404. The firm's fifty day moving average price is $191.89 and its 200 day moving average price is $187.11. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The company has a market cap of $323.50 billion, a P/E ratio of 76.25, a P/E/G ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. The firm had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. AbbVie's revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $2.31 earnings per share. As a group, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABBV. Guggenheim upped their price target on shares of AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Erste Group Bank raised shares of AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Truist Financial upped their target price on AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Cantor Fitzgerald began coverage on AbbVie in a report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 target price on the stock. Finally, Raymond James reissued an "outperform" rating and issued a $220.00 target price (up previously from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Eight equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $210.95.

Insider Buying and Selling

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at approximately $11,183,398.72. The trade was a 52.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Kevin K. Buckbee sold 18,944 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the transaction, the senior vice president now directly owns 11,496 shares in the company, valued at approximately $2,338,401.36. This represents a 62.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 113,471 shares of company stock valued at $23,426,451. 0.25% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

Several hedge funds have recently modified their holdings of ABBV. Vanguard Group Inc. boosted its holdings in AbbVie by 0.5% during the first quarter. Vanguard Group Inc. now owns 173,917,865 shares of the company's stock worth $36,439,271,000 after buying an additional 845,787 shares during the last quarter. Geode Capital Management LLC raised its holdings in AbbVie by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 37,144,933 shares of the company's stock worth $6,586,948,000 after purchasing an additional 983,888 shares during the period. Capital Research Global Investors grew its holdings in shares of AbbVie by 2.3% in the 4th quarter. Capital Research Global Investors now owns 33,983,707 shares of the company's stock valued at $6,038,898,000 after buying an additional 778,126 shares during the period. Charles Schwab Investment Management Inc. raised its stake in AbbVie by 15.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 27,436,133 shares of the company's stock worth $4,875,401,000 after buying an additional 3,599,336 shares during the period. Finally, Norges Bank acquired a new position in AbbVie in the fourth quarter valued at about $4,459,385,000. Institutional investors and hedge funds own 70.23% of the company's stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.